Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.
Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Atossa Therapeutics in a research note on Monday, August 12th. Ascendiant Capital Markets upped their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday, September 11th.
Read Our Latest Analysis on Atossa Therapeutics
Atossa Therapeutics Stock Performance
Shares of ATOS stock traded up $0.01 on Friday, reaching $1.42. 251,108 shares of the company were exchanged, compared to its average volume of 1,101,062. The company has a market cap of $178.57 million, a price-to-earnings ratio of -5.92 and a beta of 1.20. The business has a 50-day moving average price of $1.42 and a 200 day moving average price of $1.39. Atossa Therapeutics has a 1 year low of $0.62 and a 1 year high of $2.31.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. As a group, equities analysts anticipate that Atossa Therapeutics will post -0.22 earnings per share for the current year.
Institutional Trading of Atossa Therapeutics
Several large investors have recently bought and sold shares of ATOS. XTX Topco Ltd acquired a new position in Atossa Therapeutics in the 2nd quarter valued at about $29,000. SG Americas Securities LLC boosted its holdings in Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after purchasing an additional 30,037 shares during the last quarter. Cetera Advisors LLC acquired a new position in Atossa Therapeutics in the 1st quarter valued at about $72,000. Virtu Financial LLC acquired a new position in Atossa Therapeutics in the 1st quarter valued at about $151,000. Finally, Rhumbline Advisers acquired a new position in Atossa Therapeutics in the 2nd quarter valued at about $161,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
